NEW YORK--A new testing kit that measures free PSA (F-PSA), developed by a French pharmaceutical firm, may improve the positive predictive value (PPV) of PSA testing.
NEW YORK--A new testing kit that measures free PSA (F-PSA), developedby a French pharmaceutical firm, may improve the positive predictivevalue (PPV) of PSA testing.
Because of the difficulty in distinguishing between prostate malignanciesand benign prostatic hypertrophy (BPH) with PSA levels of 4 to10 ng/mL, the specificity of PSA testing is currently limited.
At the International Conference on Human Tumor Markers, NathalieBedeau, of CIS bio international (Gif-sur-Yvette), described anew assay that measures the ratio of total PSA to F-PSA.
Ms. Bedeau explained that PSA assays currently in use measuretotal PSA without making a distinction between F-PSA and PSA boundto alpha-1-antichymo-trypsin. It is known that the proportionof F-PSA is higher in patients with BPH than in those with prostatecancer. The ability to measure both total PSA and F-PSA, and toderive a ratio between the two, has been shown to nearly doublethe positive predictive value of PSA testing.
A first trial of 105 patients with prostate pathology (prostatecancer or BPH) showed that total PSA (with a cut-off of 4 ng/mL)yielded a PPV of only 48%. In the same population, the use ofF-PSA measurement and the ratio of F-PSA to total PSA yieldeda PPV of 87%.
The CIS bio international kit is available in Europe, and it holdspromise as a way to improve the specificity of PSA testing asa diagnostic tool, Ms. Bedeau commented.
[Editors' note: In the US, Hybritech has developed a similar assay,to be tested in a large clinical trial coordinated by WashingtonUniversity of St. Louis.]